People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...

Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.

RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

Decreases in daytime activity among adults with MS, indicated via accelerometers worn on their wrists, indicated later development of worse disability and brain atrophy, according to data published in ...

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- that may explain why some people develop progressive multiple sclerosis (MS), the ...